natgillin/translations-raw huggingface dataset:
vectors comprising nucleic acid molecules encoding the light chain and heavy chain of an antibody specifically binding to a second antigen, wherein the constant domains CL and CH1 are replaced by each other. 
vektore koji sadrže molekule nukleinske kiseline, koje kodiraju protutijelo slabog lanca i jakog lanca, koje se specifično veže na drugi antigen, pri čemu se konstantne domene CL i CH1 međusobno zamjenjuju;
A pharmaceutical composition comprising a bivalent, bispecific antibody according to claims 1 to 6 and at least one pharmaceutically acceptable excipient. 
Farmaceutski sastav, naznačen time, da sadrži bivalentno, bispecifično protutijelo prema bilo kojem zahtjevu od 1 do 6 te najmanje jedno farmaceutski prihvatljivo pomoćno sredstvo.
The method according to claim 1, characterized by that sodium salt of saturated or unsaturated fatty acid is used as alkaline salt of a saturated or unsaturated organic acid with long carbon chain. 
Metoda temeljem zahtjeva 1, naznačena time što se natrijeva sol zasićene ili nezasićene masne kiseline koristi kao alkalna sol zasićene ili nezasićene organske kiseline sa dugim ugljikovim lancem.
The method according to claim 2, characterized by that at least one of the followings is used as sodium salt of saturated or unsaturated fatty acid: sodium palmitate, sodium oleate, sodium linoleate and sodium stearate. 
Metoda temeljem zahtjeva 2, naznačena time što se barem jedno od slijedećeg koristi kao natrijeva sol zasićene ili nezasićene masne kiseline: natrij palmitat, natrij oleat, natrij linoleat i natrij stearat.
The method according to claim 2, characterized by that the quantity of the added sodium salt of fatty acid is chosen at a ratio of 5-6.5 compared to the quantity of the added silver. 
Metoda temeljem zahtjeva 2, naznačena time što je količina dodane natrijeve soli masne kiseline izabrana iz omjera od 5-6.5 u usporedbi sa količinom dodanog srebra.
The method according to claim 1, characterized by that the quantity of the added reducing agent is chosen at a ratio of 1-2, preferably at a ratio of 1.2, compared to the quantity of the added silver. 
Metoda temeljem zahtjeva 1, naznačena time što je količina dodanog redukcijskog agensa izabrana iz omjera od 1-2, poželjno iz omjera 1.2, u usporedbi sa količinom dodanog srebra.
The method according to claim 1, characterized by that the quantity of the added sodium carbonate is chosen at a ratio of 0,25-1, preferably at a ratio of 0.5-0.75, compared to the quantity of the added silver. 
Metoda temeljem zahtjeva 1, naznačena time što je količina dodanog natrij karbonata izabrana iz omjera od 0,25-1, poželjno iz omjera 0.5-0.75, u usporedbi sa količinom dodanog srebra.
The method according to claim 1, characterized by that the concentration of silver in the washing water is set at 10-500 ppm, preferably at 10-200 ppm, the most preferred range is 20-80 ppm. 
Metoda temeljem zahtjeva 1, naznačena time što je koncentracija srebra u vodi za pranje određena na 10-500 ppm, poželjno 10-200 ppm, najpoželjnije u rasponu od 20-80 ppm.
The method according to claim 1, characterized by that the ratio of the washing water and the fabric is 5-50, preferably 10-15, by weight. 
Metoda temeljem zahtjeva 1, naznačena time što je omjer vode za pranje i tkanine 5-50, poželjno 10-15, težinski.
The method according to claim 1, characterized by that at least one of the following compounds is used as reducing agent: ascorbic acid, D-glucose, hydroxyl amine, sodium borohydride. 
Metoda temeljem zahtjeva 1, naznačena time što se barem jedan od slijedećih spojeva koristi kao redukcijski agens: askorbinska kiselina, D-glukoza, hidroksil amin, natrij borohidrid.
The method according to claim 1, characterized by that the washing and the soaking processes are performed in a washing machine during 3-50 minutes, preferably during 8-30 minutes. 
Metoda temeljem zahtjeva 1, naznačena time što se postupci pranja i omekšavanja izvode u perilici tijekom 3-50 minuta, poželjno tijekom 8-30 minuta.
The method according to claim 1, characterized by that the yarns should contain at least one of the following materials: wool, cotton, silk. 
Metoda temeljem zahtjeva 1, naznačena time što prediva trebaju sadržavati barem jedan od slijedećih materijala: vunu, pamuk, svilu.
The process according to one of the preceding claims, wherein the acid has a pKa at 25°C of 2.5 or less, preferably a pKa at 25°C of 0 or less, and is preferably sulphuric acid, hydrochloric acid, or mixtures thereof. 
Postupak prema jednom od prethodnih zahtjeva, pri čemu kiselina ima pKa pri 25°C 2.5 ili manje, poželjno pKapri 25°C od 0 ili manje, te je poželjno sumporna kiselina, klorovodična kiselina, ili njihova smjesa.
The process according to claim 4, wherein the acid has a pKa at 25°C of from 0 to 2.5, and is preferably H2SO3, HSO4-, H3PO4, oxalic acid, or mixtures thereof. 
Postupak prema zahtjevu 4, pri čemu kiselina ima pKapri 25°C od 0 do 2.5, te je preporučeno H2SO3, HSO4, H3PO4, oksalna kiselina, ili njihova smjesa.
The process according to one of the preceding claims, wherein the natural calcium carbonate is reacted with the acid and/or the carbon dioxide in the presence of at least one compound selected from the group consisting of silicate, preferably selected from an aluminium silicate, a calcium silicate, or an earth alkali metal silicate; silica, aluminium hydroxide, earth alkali metal aluminate, magnesium oxide, or mixtures thereof. 
Postupak prema jednom od prethodnih zahtjeva, pri čemu prirodni kalcij karbonat reagira sa kiselinom i/ili ugljičnim dioksidom u prisutnosti barem jednog spoja izabranog iz skupine koja se sastoji od silikata, poželjno izabranog od aluminij silikata, kalcij silikata, ili zemno alkalnog metalnog silikata; silike, aluminij hidroksida, zemno alkalnog metalnog aluminata, magnezij oksida, ili njihovih smjesa.
The process according to one of the preceding claims, wherein the surface-reacted natural calcium carbonate is added to the water to be purified in the form of an aqueous suspension, optionally stabilised with a dispersant, especially a cationic dispersant, if the surface-reacted natural calcium carbonate has been prepared from marble in the presence of at least one silicate. 
Postupak prema jednom od prethodnih zahtjeva, pri čemu se površinski-reagirani prirodni kalcij karbonat dodaje u vodu koju treba pročistiti u obliku vodene suspenzije, opcionalno stabilizirane sa disperzantom, posebno kationskim disperzantom, ako je površinski-reagirani prirodni kalcij karbonat pripremljen od mramora u prisutnosti barem jednog silikata.
The process according to one of the preceding claims, wherein the polymeric flocculant is anionic and/or cationic. 
Postupak prema jednom od prethodnih zahtjeva, pri čemu je polimerni flokulant anionski i/ili kationski.
The process according to one of the preceding claims, wherein the polymeric flocculant is polyacrylamide. 
Postupak prema jednom od prethodnih zahtjeva, pri čemu je polimerni flokulant poliakrilamid.
The process according to claim 17, wherein the water to be purified contains heavy metal impurities, organic impurities, microorganisms, and/or at least one compound selected from polycyclic compounds, cholesterol, and/or endocrine disrupting compounds. 
Postupak prema zahtjevu 17, pri čemu voda koju treba pročistiti sadrži nečistoće teških metala, organske nečistoće, mikroorganizme, i/ili barem jedan spoj izabran od policikličnih spojeva, kolesterola, i/ili spojeva koji izazivaju endokrine poremećaje.
The process according to claim 18, wherein, if the water to be purified contains at least one compound selected from polycyclic compounds, cholesterol, and/or endocrine disrupting compounds, the surface-reacted natural calcium carbonate is used in combination with activated carbon. 
Postupak prema zahtjevu 18, pri čemu, ako voda koju treba pročistiti sadrži barem jedan spoj izabran od policikličnih spojeva, kolesterola, i/ili spojeva koji izazivaju endokrine poremećaje, površinski-reagirani prirodni kalcij karbonat se koristi u kombinaciji sa aktivnim ugljenom.
Use of the surface-reacted natural calcium carbonate in combination with a polymeric flocculant as defined in one of the claims 1 to 23 for water purification. 
Uporaba površinski-reagiranog prirodnog kalcij karbonata u kombinaciji sa polimernim flokulantom kao što je definirano u jednom od zahtjeva 1 do 15 za pročišćavanje vode.
A composite material obtained by the process according to any one of claims 1 to 19, comprising the surface-reacted natural calcium carbonate as defined in one of the claims 1 to 15 and at least one of the impurities selected from heavy metal impurities, microorganisms, polycyclic compounds, cholesterol and endocrine disrupting compounds, preferably further comprising activated carbon. 
Kompozitni materijal dobiven postupkom prema bilo kojem od zahtjeva 1 do 19, koji sadrži površinski-reagirani prirodni kalcij karbonat kao što je definiran u jednom od zahtjeva 1 do 15 i barem jednu od nečistoća izabranih iz nečistoća teških metala, organskih nečistoća, mikroorganizama, policikličnih spojeva, kolesterola i spojeva koji izazivaju endokrine poremećaje, te poželjno nadalje sadrži aktivni ugljen.
each R5 and R6 is independently selected from alkoxy, alkyl, aryl, halo, haloalkyl, hydroxy, and -NRaRb, wherein the alkyl can optionally form a fused three- to six-membered ring with an adjacent carbon atom, wherein the three- to six-membered ring is optionally substituted with one or two alkyl groups; 
svaki R5 i R6 je nezavisno izabran između alkoksi, alkil, aril, halo, haloalkil, hidroksi, i -NRaRb, gdje alkil može po izboru formirati fuzionirani tri- do šesteročlani prsten sa susjednim atomom ugljika, gdje je tri- do šesteročlani prsten po izboru supstituiran s jednom ili dvije alkilne skupine;
The composition of claim 37 wherein at least one of the additional compounds is selected from interleukin 2, interleukin 6, interleukin 12, a compound that enhances the development of a type 1Helper T cell response, interfering RNA, anti-sense RNA, Imiqimod, ribavirin, an inosine 5'-monophospate dehydrogenase inhibitor, amantadine, and rimantadine. 
Smjesa prema zahtjevu 37 gdje se barem jedan od dodatnih spojeva izabire između interleukina 2, interleukina 6, interleukina 12, spoja koji pojačava nastanak odgovora pomoćnih T stanica tipa 1, interferirajuće RNA, anti-sense (besmislene) RNA, Imiqimod, ribavirina, inhibitora inozin 5'-monofosfat dehidrogenaze, amantadina i rimantadina.
The compound for use according to claim 3 wherein at least one of the additional compounds is selected from interleukin 2, interleukin 6, interleukin 12, a compound that enhances the development of a type 1 helper T cell response, interfering RNA, anti-sense RNA, Imiqimod, ribavirin, an inosine 5'-monophospate dehydrogenase inhibitor, amantadine, and rimantadine. 
Spoj prema zahtjevu 43 gdje gdje se barem jedan od dodatnih spojeva izabire između interleukina 2, interleukina 6, interleukina 12, spoja koji pojačava nastanak odgovora pomoćnih T stanica tipa 1, interferirajuće RNA, anti-sense (besmislene) RNA, Imiqimod, ribavirina, inhibitora inozin 5'-monofosfat dehidrogenaze, amantadina i rimantadina.
Pharmaceutical composition comprising a pharmaceutical formulation including an amount of a PDE4 inhibitor, an amount of a HMG-CoA reductase inhibitor and at least one pharmaceutically acceptable auxiliary, wherein the PDE4 inhibitor is selected from the group consisting of ROFLUMILAST, a pharmaceutically acceptable salt of ROFLUMILAST, ROFLUMILAST-N-oxide and a pharmaceutically acceptable salt of ROFLUMILAST-N-oxide, the HMG-CoA reductase inhibitor is ROSUVASTATIN or a pharmaceutically acceptable salt thereof, and wherein the first amount and the second amount together comprise an effective amount for the preventive or curative treatment of an inflammatory pulmonary disease. 
Farmaceutski sastav, naznačen time, da obuhvaća farmaceutsku formulaciju koja uključuje jednu količinu PDE4-inhibitora, jednu količinu inhibitora reduktaze HMG-CoA i barem jedno farmaceutski prihvatljivo pomoćno sredstvo, dok je PDE4-inhibitor odabran iz skupine koja sadrži ROFLUMILAST, farmaceutski prihvatljivu sol ROFLUMILASTA, ROFLUMILAST-N-oksid i farmaceutski prihvatljivu sol ROFLUMILAST-N-oksida, gdje inhibitor reduktaze HMG-CoA je SIMVASTATIN ili njegova farmaceutski prihvatljiva sol, pri čemu prva količina i druga količina zajedno sastavljaju djelotvornu količinu za preventivno i kurativno liječenje upalne bolesti pluća.
Pharmaceutical composition according to any one of claims 27, 30, 31, 32 or 33, wherein the inflammatory pulmonary disease is selected from the group consisting of asthma, COPD, sclerosis, alveolitis, sarcoidosis, idiopathic pulmonary fibrosis and pulmonary hypertension. 
Farmaceutski sastav prema bilo kojem zahtjevu 27, 30, 31, 32 ili 33, naznačen time, da je upalna bolest pluća odabrana iz skupine koju čine: astma, COPD, skleroza, alveolitis, sarkoidoza, idiopatska plućna fibroza i plućna hipertenzija.
A compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein u and v are each independently 0, 1, or 2; and each R1 and R2 is independently selected from alkoxy, alkoxyalkyl, alkyl, arylalkoxycarbonyl, carboxy, formyl, halo, haloalkyl, hydroxyalkyl, (NRaRb)alkyl, and (NRaRb)carbonyl. 
Spoj prema zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, gdje u i v su svaki nezavisno 0, 1, ili 2; i svaki R1 i R2 su nezavisno izabrani između alkoksi, alkoksialkil, alkil, arilalkoksikarbonil, karboksi, formil, halo, haloalkil, hidroksialkil, (NRaRb)alkil i (NRaRb)karbonil.
A compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein q and s are independently 0, 1, or 2; and each R5 and R6 is independently selected from alkyl, aryl, halo, and hydroxy, wherein the alkyl can optionally form a fused three- to six-membered ring with an adjacent carbon atom, wherein the three- to six-membered ring is optionally substituted with one or two alkyl groups. 
Spoj prema zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, gdje q i s su nezavisno 0, 1, ili 2; i svaki R5 i R6 je nezavisno izabran između alkil, aril, halo i hidroksi, gdje alkil može po izboru formirati fuzionirani tri- do šesteročlani prsten sa susjednim atomom ugljika, gdje je tri- do šesteročlani prsten po izboru supstituiran s jednom ili dvije alkilne skupine.
A compound of claim 1 of Formula (II) or a pharmaceutically acceptable salt thereof, wherein q and s are independently 0, 1, or 2; 
Spoj prema zahtjevu 1 Formule (II) [image] ili njegova farmaceutski prihvatljiva sol, gdje q i s su nezavisno 0, 1, ili 2;
A compound of claim 1 of Formula (III) or a pharmaceutically acceptable salt thereof, wherein q and s are independently 0, 1, or 2; 
Spoj prema zahtjevu 1 Formule (III) [image] ili njegova farmaceutski prihvatljiva sol, gdje q i s su nezavisno 0, 1, ili 2;
The compound of claim 42 further comprising using one or two additional compounds having anti-HCV activity prior to, after or simultaneously with the compound of claim 1, or a pharmaceutically acceptable salt thereof. 
Spoj prema zahtjevu 42 koji dalje obuhvaća uporabu jednog ili dva dodatna spoja s djelovanjem protiv HCV-a prije, nakon ili istodobno sa spojem prema zahtjevu 1, ili njegovom farmaceutski prihvatljivom soli.
The compound of claim 43 wherein at least one of the additional compounds is selected from interleukin 2, interleukin 6, interleukin 12, a compound that enhances the development of a type 1Helper T cell response, interfering RNA, anti-sense RNA, Imiqimod, ribavirin, an inosine 5'-monophospate dehydrogenase inhibitor, amantadine, and rimantadine. 
Spoj prema zahtjevu 43 gdje gdje se barem jedan od dodatnih spojeva izabire između interleukina 2, interleukina 6, interleukina 12, spoja koji pojačava nastanak odgovora pomoćnih T stanica tipa 1, interferirajuće RNA, anti-sense (besmislene) RNA, Imiqimod, ribavirina, inhibitora inozin 5'-monofosfat dehidrogenaze, amantadina i rimantadina.
a C3-8 cycloalkyl-C1-6 alkyl group (wherein C3-8 cycloalkyl is optionally substituted by the same or different 1 to 5 substituents selected from the following group B); 
-8cikloalkil-C1-6 alkil skupina (gdje C3-8 cikloalkil je opcijski supstituiran sa 1 do 5 istih ili različitih supstituenata izabranih iz slijedeće skupine B);
The compound for use according to claim 3 wherein at least one of the additional compounds is selected from interleukin 2, interleukin 6, interleukin 12, a compound that enhances the development of a type 1 helper T cell response, interfering RNA, anti-sense RNA, Imiqimod, ribavirin, an inosine 5'-monophospate dehydrogenase inhibitor, amantadine, and rimantadine. 
Smjesa prema zahtjevu 37 gdje se barem jedan od dodatnih spojeva izabire između interleukina 2, interleukina 6, interleukina 12, spoja koji pojačava nastanak odgovora pomoćnih T stanica tipa 1, interferirajuće RNA, anti-sense (besmislene) RNA, Imiqimod, ribavirina, inhibitora inozin 5'-monofosfat dehidrogenaze, amantadina i rimantadina.
The use according to claim 10 wherein at least one of the additional compounds is selected from interleukin 2, interleukin 6, interleukin 12, a compound that enhances the development of a type 1 helper T cell response, interfering RNA, anti-sense RNA, Imiqimod, ribavirin, an inosine 5'-monophospate dehydrogenase inhibitor, amantadine, and rimantadine. 
Spoj prema zahtjevu 43 gdje gdje se barem jedan od dodatnih spojeva izabire između interleukina 2, interleukina 6, interleukina 12, spoja koji pojačava nastanak odgovora pomoćnih T stanica tipa 1, interferirajuće RNA, anti-sense (besmislene) RNA, Imiqimod, ribavirina, inhibitora inozin 5'-monofosfat dehidrogenaze, amantadina i rimantadina.
Multiparticulates according to any of claims 1 to 3, wherein the plasticiser is chosen from cetyl alcohol, stearyl alcohol, cetostearyl alcohol, sorbitol, sucrose, high molecular weight polyethylene glycol, dibutyl sebacate, tributyl citrate, triethyl citrate, propylene glycol and low molecular weight polyethylene glycol. 
Multičestice prema bilo kojem od zahtjeva 1 do 3, gdje se plastifikator izabire između cetilnog alkohola, stearil alkohola, cetostearil alkohola, sorbitola, saharoze, polietilen glikol visoke molekulske težine, dibutil sebacat, tributil citrat, trietil citrat, propilen glikol i polietilen glikol niske molekulske težine.
Multiparticulates according to claim 4, wherein the plasticiser is a high molecular weight polyethylene glycol. 
Multičestice prema zahtjevu 4, gdje je plastifikator polietilen glikol visoke molekulske težine.
Multiparticulates according to any one of claims 1 to 10, wherein the percentage amounts of the ingredients (a) to (e) are as given in the following table, based on the total weight of the five ingredients: 
Multičestice prema bilo kojem od zahtjeva 1 do 10, gdje su količine sastojaka od (a) do (e) dane u postotcima u sljedećoj tablici, na temelju ukupne težine pet sastojaka:
The method for detecting cell proliferative disorders according to claim 1 or 2, comprising: 
Postupak otkrivanja raka pluća, dojke ili mjehura prema zahtjevu 1 ili 2, obuhvaća:
Use of a compound of formula (I') or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment of an inflammatory disorder: 
Uporaba spoja s formulom (I') ili njegove farmaceutski prihvatljive soli, naznačena time da je za pripravu lijeka za liječenje upalnog poremećaja:
A compound of formula (I') or a pharmaceutically acceptable salt thereof, for use in the treatment of an inflammatory disorder: 
Spoj s formulom (I') ili njegova farmaceutski prihvatljiva sol, naznačen time da je za uporabu kod liječenja upalnog poremećaja:
A pharmaceutically acceptable composition comprising, as active ingredient, a compound of formula (I') or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient and/or carrier: 
Farmaceutski prihvatljiv pripravak naznačen time da kao aktivnu tvar sadrži spoj s formulom (I') ili njegovu farmaceutski prihvatljivu sol, te barem jednu farmaceutski prihvatljivu pomoćnu tvar i/ili nosač:
A compound of general formula (I'): 
Spoj sa općom formulom (I'):
Use of a compound of formula (I) or (I'), or the compound of formula (I) or (I') for use, according to claim 11 where the inflammatory disorder is asthma, allergic rhinitis or chronic obstructive pulmonary disease. 
Uporaba spoja s formulom (I) ili (I'), ili spoj s formulom (I) ili (I') za uporabu, prema zahtjevu 11 naznačen time daje upalni poremećaj astma, alergijski rinitis ili kronična opstruktivna plućna bolest.
A pharmaceutically acceptable composition according to claim 7 or 8, for use in treatment, amelioration or prophylaxis of the symptoms of an inflammatory disorder. 
Farmaceutski prihvatljiv pripravak prema zahtjevu 7 ili 8, naznačen time da je za uporabu kod liječenja, ublažavanja ili profilakse simptoma upalnog poremećaja.
Cosmetic use of a glycogen containing less than 1,000 ppm of nitrogen and less than 1% by weight of reducing sugars as a velvet agent (i.e. an agent to obtain the sensory effect of a soft and smooth skin) in a cosmetic composition for skin application. 
Kozmetička upotreba glikogena koji sadrži manje od 1000 ppm dušika i manje od 1 % masenog udjela reducirajućih šećera kao baršunastih sredstava (odnosno sredstava da bi se dobio osjetni učinak mekane i glatke kože) u kozmetičkom pripravku za primjenu na koži.
Cosmetic use according to claim 3, characterised in that the said cosmetically-acceptable vehicle is selected from the group comprising emulsifiers, hydrating agents, solvents, emollients, stabilisers, viscosity agents, preservatives, lubricants, sequestrating or chelating agents, fillers, fragrances, perfumes, absorbents, colouring agents and opacifiers, antioxidants, plant extracts and oils, vitamins, protective substances, essential oils, keratin-active substances and amino acids. 
Kozmetička upotreba prema zahtjevu 3, naznačena time da je spomenuti kozmetičko-prihvatljivi nosač odabran iz skupine koju čine sredstva za emulgiranje, hidratizirajuća sredstva, otapala, tvari za omekšavanje, stabilizatori, sredstva za povećavanje viskoznosti, konzervansi, sredstva za podmazivanje, inhibirajuća ili kelatirajuća sredstva, punila, mirisi, parfemi, apsorbenti, sredstva za bojenje i neprozirne tvari, antioksidansi, biljni ekstrakti i ulja, vitamini, zaštitne tvari, eterična ulja, keratin-aktivne tvari i aminokiseline .
Cosmetic use according to Claim 7, characterised in that the said semi-solid formulation comprises at least one solvent, at least one emulsifier, at least one viscosity agent, at least one hydrating agent, at least one emollient, and at least one preservative. 
Kozmetička upotreba prema zahtjevu 7, naznačena time da spomenuta polukruta formulacija sadrži minimalno jedno otapalo, minimalno jedan emulgator, najmanje jedno sredstvo za poboljšanje viskoznosti, najmanje jedno hidratantno sredstvo, barem jedno sredstvo za omekšavanje, te minimalno jedan konzervans.
Cosmetic use according to any one of Claims 6 to 9, characterised in that the said solvent is selected from the group comprising water, alcohols, ketones, glycols, polyethylene glycols, alkyl acetates, isoparaffins, cycloalkyls, glycerine, natural and synthetic oils, natural and synthetic triglycerides. 
Kozmetička upotreba prema bilo kojem zahtjevu od 6 do 9, naznačena time da je spomenuto otapalo odabrano iz skupine koja sadrži vodu, alkohole, ketone, glikole, polietilen glikole, alkil acetate, izoparafine, cikloalkile, glicerine, prirodna i sintetička ulja, prirodne i sintetičke trigliceride.